The clinical value of complete blood count-based immun parameter in predicting testicular cancer pathology and prognosis

Abstract

Aim: The management of testicular cancer (TC) requires more specific and applicable biomarkers. We aimed to determine the ability of complete blood count (CBC) based inflammatory markers to predict tumor pathology and prognosis in TC. Methods: Patients who underwent inguinal orchiectomy for testicular germ cell tumors (TGCTs) at our hospital between January 2011 and December 2022 were included in the study. The medical records of patients with pathologically confirmed TC, including demographics, preoperative tumor markers, preoperative CBC, tumor characteristics, pathological outcomes, postoperative follow-up, and survival outcomes, were retrospectively collected. CBC-based inflammatory markers were compared between seminomatous and non-seminomatous TGCTs. To determine the independent prognostic significance of survival, the data were analyzed and fitted to the multivariate Cox proportional risk regression model. Results: The median follow-up was 48 (1-140) months. In our chord, 69 patients had seminomatous TGCTs (Group 1), and 66 had non-seminomatous TGCTs (Group 2). The median ages of Groups 1 and 2 were 35 (22-74) years and 31 (21-72) years(p